CDKN2A Mutation and Higher Nevus Count Can Increase Risk for Subsequent Primary Melanoma
Source: Dermatology Advisor, October 2023
There is a high certainty of evidence that patients with CDKN2A mutation and a moderate or high nevus count had significantly increased risk for multiple primary melanomas, according to study results published in the British Journal of Dermatology.
Researchers conducted a systematic review and meta-analysis to identify specific risk factors for developing subsequent primary melanoma. They searched 4 databases (CINAHL, CENTRAL, EMBASE, and MEDLINE) for studies published between 1982 and August 2022. A total of 27 studies with 388,424 patients were included in their analysis.
The researchers found that men were at higher risk for subsequent primary melanoma than women (low certainty of evidence; hazard ratio [HR], 1.46; 95% CI, 1.40-1.53), as were older patients (moderate certainty of evidence; HR, 1.19; 95% CI, 1.14-1.24). In addition, compared with a low/moderate family history of melanoma, a strong family history was found to greatly increase the risk of developing subsequent melanoma (low certainty of evidence; odds ratio [OR], 1.79).